X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs LUPIN LTD - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA LUPIN LTD ASTRAZENECA PHARMA/
LUPIN LTD
 
P/E (TTM) x 90.6 16.6 544.2% View Chart
P/BV x 12.9 3.9 332.7% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ASTRAZENECA PHARMA   LUPIN LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
LUPIN LTD
Mar-16
ASTRAZENECA PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,2852,127 60.4%   
Low Rs6341,294 49.0%   
Sales per share (Unadj.) Rs189.6304.1 62.3%  
Earnings per share (Unadj.) Rs-0.250.4 -0.4%  
Cash flow per share (Unadj.) Rs3.860.7 6.3%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs68.6243.8 28.2%  
Shares outstanding (eoy) m25.00450.58 5.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.15.6 90.0%   
Avg P/E ratio x-4,712.733.9 -13,884.1%  
P/CF ratio (eoy) x249.628.2 885.4%  
Price / Book Value ratio x14.07.0 199.2%  
Dividend payout %014.9 0.0%   
Avg Mkt Cap Rs m23,988770,740 3.1%   
No. of employees `0001.616.4 9.5%   
Total wages/salary Rs m1,60521,077 7.6%   
Avg. sales/employee Rs Th3,040.28,379.6 36.3%   
Avg. wages/employee Rs Th1,029.21,289.0 79.8%   
Avg. net profit/employee Rs Th-3.31,388.7 -0.2%   
INCOME DATA
Net Sales Rs m4,740137,016 3.5%  
Other income Rs m921,877 4.9%   
Total revenues Rs m4,832138,893 3.5%   
Gross profit Rs m-13037,535 -0.3%  
Depreciation Rs m1014,635 2.2%   
Interest Rs m0446 0.0%   
Profit before tax Rs m-13934,330 -0.4%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m511,536 0.0%   
Profit after tax Rs m-522,707 -0.0%  
Gross profit margin %-2.727.4 -10.0%  
Effective tax rate %-3.733.6 -10.9%   
Net profit margin %-0.116.6 -0.6%  
BALANCE SHEET DATA
Current assets Rs m2,72697,790 2.8%   
Current liabilities Rs m2,43553,872 4.5%   
Net working cap to sales %6.132.1 19.2%  
Current ratio x1.11.8 61.7%  
Inventory Days Days7485 87.1%  
Debtors Days Days41121 33.6%  
Net fixed assets Rs m1,03586,379 1.2%   
Share capital Rs m50901 5.5%   
"Free" reserves Rs m942105,735 0.9%   
Net worth Rs m1,716109,844 1.6%   
Long term debt Rs m053,739 0.0%   
Total assets Rs m4,156224,378 1.9%  
Interest coverage xNM77.9-  
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.10.6 186.8%   
Return on assets %-0.110.3 -1.2%  
Return on equity %-0.320.7 -1.4%  
Return on capital %021.2 0.0%  
Exports to sales %5.749.1 11.6%   
Imports to sales %6.57.4 86.8%   
Exports (fob) Rs m27067,244 0.4%   
Imports (cif) Rs m30610,199 3.0%   
Fx inflow Rs m37571,405 0.5%   
Fx outflow Rs m47017,807 2.6%   
Net fx Rs m-9653,598 -0.2%   
CASH FLOW
From Operations Rs m-8-3,690 0.2%  
From Investments Rs m-146-69,434 0.2%  
From Financial Activity Rs m86258,126 1.5%  
Net Cashflow Rs m709-14,998 -4.7%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 75.0 0.2 37,500.0%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 15.7 31.9 49.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.1 90.1%  
Shareholders   12,856 98,259 13.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   IPCA LABS  SANOFI INDIA  PANACEA BIOTECH  MERCK LTD  NOVARTIS  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 22, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS